



Design, synthesis and biological evaluation of N-substituted α -hydroxyimides and 1,2,3-oxathiazolidine-4-one-2,2-dioxides with anticonvulsant activity

Laureano L. Sabatier, Pablo H. Palestro, Andrea V. Enrique, Valentina Pastore, María L. Sbaraglini, Pedro Martín & Luciana Gavernet

To cite this article: Laureano L. Sabatier, Pablo H. Palestro, Andrea V. Enrique, Valentina Pastore, María L. Sbaraglini, Pedro Martín & Luciana Gavernet (2019) Design, synthesis and biological evaluation of N-substituted α -hydroxyimides and 1,2,3-oxathiazolidine-4-one-2,2-dioxides with anticonvulsant activity, Journal of Enzyme Inhibition and Medicinal Chemistry, 34:1, 1465-1473, DOI: [10.1080/14756366.2019.1651722](https://doi.org/10.1080/14756366.2019.1651722)

To link to this article: <https://doi.org/10.1080/14756366.2019.1651722>



© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



View supplementary material [↗](#)



Published online: 14 Aug 2019.



Submit your article to this journal [↗](#)



View Crossmark data [↗](#)

RESEARCH PAPER



Design, synthesis and biological evaluation of N-substituted α -hydroxyimides and 1,2,3-oxathiazolidine-4-one-2,2-dioxides with anticonvulsant activity

Laureano L. Sabatier^a, Pablo H. Palestro^a, Andrea V. Enrique^b, Valentina Pastore^b, María L. Sbaragini^a, Pedro Martín^b and Luciana Gavernet^a

^aMedicinal Chemistry, Department of Biological Sciences, Faculty of Exact Sciences, National University of La Plata, La Plata, Argentina;
^bInstituto de Estudios Inmunológicos y Fisiopatológicos (IIFP), CONICET—Universidad Nacional de la Plata, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata, Argentina

ABSTRACT

In this investigation, we studied a family of compounds with an oxathiazolidine-4-one-2,2-dioxide skeleton and their amide synthetic precursors as new anticonvulsant drugs. The cyclic structures were synthesized using a three-step protocol that include solvent-free reactions and microwave-assisted heating. The compounds were tested *in vivo* through maximal electroshock seizure test in mice. All the structures showed activity at the lower doses tested (30 mg/Kg) and no signs of neurotoxicity were detected. Compound encoded as **1g** displayed strong anticonvulsant effects in comparison with known anticonvulsants ($ED^{50} = 29$ mg/Kg). First approximations about the mechanisms of action of the cyclic structures were proposed by docking simulations and *in vitro* assays against sodium channels (patch clamp methods).

ARTICLE HISTORY

Received 15 May 2019
Revised 23 July 2019
Accepted 25 July 2019

KEYWORDS

Epilepsy; 1,2,3-oxathiazolidine-4-one-2,2-dioxide; α -hydroxyimides; docking; sodium channels blockers; MES test; microwave-assisted synthesis

Introduction


The advances in the understanding of epilepsy and its comorbid conditions have triggered notable improvements of the pharmacological options for the treatment of this disorder. The new developments include innovative processes like the use of 3D printing technologies for improving the delivery of anticonvulsant drugs (ACD)¹, but mostly involve the introduction of new approved compounds². There are more than 20 ACDs currently available for use in the United States, which means that the therapeutic arsenal has been doubled over the past 15 years². However, the discovery of more effective compounds continues to be a top priority for researches in the field³. According to World Health Organization, there are 50 million people worldwide with epilepsy and one-third of them are unable to control the disorder with ACDs⁴. Therefore, most of the efforts are now focused on lowering the number of patients that experience resistance to the available medications. In this investigation, we studied a family of structures with an oxathiazolidine-4-one-2,2-dioxide skeleton and their synthetic precursors as new candidates of ACDs. The rationale for selecting the cyclic scaffold was based on its bioisosteric relationship with the classical ACD phenytoin (Figure 1). The anticonvulsant action of phenytoin was identified by Putnam and Merritt in 1937 by means of their pioneering model for rapid screening of ACD, which tested the ability of candidates to protect against electroshock-induced convulsions in cats⁶. This phenotypic screening was the starting point for the development of acute models of seizures in animals that successfully identified the majority of

known ACDs⁷. Even today phenytoin is used in epilepsy treatment for generalized tonic-clonic and partial seizures⁸.

In a previous work, on some N-derivatives of oxathiazolidine-4-one-2,2-dioxides, we synthesized only four new compounds with the scaffold and they showed activity against the Maximal Electroshock Seizure (MES) test in mice (Figure 1)⁵. The MES test consist of the electrical induction of the convulsions and it is associated with the generalized tonic-clonic seizures⁹. Interestingly, the synthetic precursors of the cycles, α -hydroxyamides, also exhibited anticonvulsant action in MES test⁵. These results encouraged us to expand the set with new structures, with the aim of exploring the anticonvulsant action in both α -hydroxyamides and their cyclic derivatives.

The synthetic procedure involved the preparation of the α -hydroxyamides from the ammonolysis reaction between 2-hydroxyisobutyl methyl ester and the corresponding amine followed by a cyclization reaction and the oxidation of the product⁵. Both sets of α -hydroxyamides and oxathiazolidine-4-one-2,2-dioxide derivatives were evaluated against MES test in mice⁹. Toxicity was also tested by the standardized Rotorod test, which is also included in the primary phase of anticonvulsant screening program⁹. To get inside into the possible mode of action of the compounds, we analysed the capacity of the structures of blocking the Nav1.2 isoform of the voltage-gated sodium channels (VGSC). The selection of the target was supported on preliminary studies about one compound of the cyclic family, the 3-butyl-5,5-dimethyl oxathiazolidine-4-one-2,2-dioxide (compound D, Figure 1), which

CONTACT Luciana Gavernet  lgavernet@biol.unlp.edu.ar, lgavernet@gmail.com  Medicinal Chemistry, Department of Biological Sciences, Faculty of Exact Sciences, National University of La Plata, La Plata, Argentina

 Supplemental data for this article can be accessed [here](#).

© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.




Figure 1. Chemical structure of phenytoin (A), and the oxathiazolidine-4-one-2,2-dioxides previously synthesized (B–E).⁵

has sodium channels (VGSC) blocking properties¹⁰. Additionally, it is well known that Nav1.2 isoform is the molecular target of many ACDs like phenytoin, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine, zonisamide and lacosamide^{11,12}. First, we simulated the interaction between the compounds synthesized and a 3D model of the Nav1.2 isoform by means of docking protocols. Then, the docking candidates and other structures predicted as inactive were tested on Nav1.2 currents using the patch clamp technique.

Materials and methods

Chemistry

Microwave reactions were carried out in an Anton-Paar-monowave-300 reactor (monowave, maximum power 850 W, temperature control via IR-sensor, vial volume: 10–30 mL). Melting points were determined using capillary tubes with an electrothermal melting point apparatus and are uncorrected. Thin-layer chromatography (TLC) was performed with aluminium backed sheets with silica gel 60 F254 (Merck, ref 1.05554), and the spots were visualized with 254 nm UV light and 5% aqueous solution of ammonium molybdate (VI) tetrahydrate. Column chromatography was performed on silica gel 60 (70–230 mesh, Merck, ref 1.07734.2500). ¹H and ¹³C NMR spectra were recorded on a Bruker Avance 500 MHz spectrometer. The chemical shifts were reported in ppm (δ scale) relative to internal TMS, and coupling constants were reported in Hertz (Hz).

Synthesis of α -hydroxyamides 1(a–g). Compounds **1d** and **1e** were previously synthesized^{5,13–17}. MW-assisted free solvent synthesis was performed by means of the previously developed procedures.⁵ α -hydroxyisobutylmethyl ester (20 mmol) was put into a dry vessel with the corresponding amine (24 mmol) and a Teflon-coated magnetic stirring bar. The reactor was set at 150 °C, the reaction time was 30 min and the mixtures were monitored by TLC. Amides **1b**, **1d** and **1f**, were also synthesized by conventional heating and 30% w/w of 1,5,7-triazabicyclo [4.4.0] dec-5-ene (TBD) as catalyst to improve the yield of the products achieved with MW heating. These reactions were conducted at 70 °C during 20 h of reaction and the yields with this alternative route increased from 24 to 32% for **1b**, 5 to 56% for **1d** and 18 to 47% for **1f**.

The isolation steps were similar in both conventional and microwave assisted heating. After the reaction was concluded, dichloromethane (30 mL) was added and the solution was washed with 10 mL of 5% v/v hydrochloric acid (2 \times) and brine (1 \times). The combined organic layers were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was then purified by silica column chromatography and/or crystallization. The pure products were obtained as white solids in all cases except for compound **1a**.

N-hexyl-2-hydroxyisobutylamide (1a). Yield 40% (oil). ¹H NMR (500 MHz, CDCl₃) δ 6.75 (s, 1H, –NH), 3.26 (m, 2H, –CH₂–NH), 1.53 (m, 2H, –CH₂–CH₂–NH–), 1.47 (s, 6H, –CH₂–), 1.32 (s, 6H,

(–CH₃)₂), 0.90 (t, J = 6.7 Hz, 3H, –CH₃). ¹³C NMR (126 MHz, CDCl₃) δ 175.91 (CO), 73.29 (–C–OH), 39.48 (–CH₂–NH–), 31.16 (–CH₂–(CH₂)₃–NH–), 29.51 (–CH₂–CH₂–NH–), 27.61 ((–CH₃)₂), 26.54 (–CH₂–(CH₂)₂–NH–), 22.76 (–CH₂–(CH₂)₄–NH–), 13.8 (–CH₃).


N-isopropyl-2-hydroxyisopropylamide (1b). Yield with MW heating: 24%, yield with conventional heating 32% (mp: 66–67, hexane). ¹H NMR (500 MHz, CDCl₃) δ 6.71 (s, 1H, –NH), 4.05–3.88 (m, 1H, –CH), 3.40 (s, 1H, –OH), 1.43 (s, 6H, (–CH₃)₂), 1.16 (d, J = 6.6 Hz, 6H, –CH–(CH₃)₂). ¹³C NMR (126 MHz, CDCl₃) δ 175.96 (CO), 72.52 (–C–OH), 40.64 (–NH–CH–), 27.54((–CH₃)₂), 22.24(–CH–(CH₃)₂).

N-isobutyl-2-hydroxyisobutylamide (1c). Yield 57% (mp: 104–105, hexane). ¹H NMR (500 MHz, CDCl₃) δ 6.17 (s, 1H, –NH), 3.08 (t, J = 6.5 Hz, 2H, –CH₂–), 1.84–1.71 (m, 1H, –CH), 1.45 (s, 6H, (–CH₃)₂), 0.93 (d, J = 6.7 Hz, 6H, –CH–(CH₃)₂) ¹³C NMR (126 MHz, CDCl₃) δ 176.23 (CO), 73.33(–C–OH), 46.37(–NH–CH₂–), 28.55(–NH–CH₂–CH–), 27.95 ((–CH₃)₂), 20.02(–CH–(CH₃)₂).

N-(1-ethyl) benzyl-2-hydroxyisobutylamide (1f). Yield with MW heating: 18%, Yield with conventional heating: 47% (mp: 63–64, hexane). ¹H NMR (500 MHz, CDCl₃) δ 7.38–7.27 (m, 5H, Ar), 7.02 (1, 1H, –NH), 4.86 (q, 1H, –NH–CH–Ar), 2.13 (s, 1H, –OH), 1.86 (p, J = 7.3 Hz, 2H, –CH₂–), 1.49 (s, 3H, –CH₃), 1.44 (s, 3H, –CH₃), 0.93 (t, J = 7.4 Hz, 3H, –CH₂–CH₃). ¹³C NMR (126 MHz, CDCl₃) δ 175.50 (CO), 142.15 – 126.49 (Ar), 73.68 (–C–OH), 54.54 (–NH–CH–), 29.38–28.06 ((–CH₃)₂), 27.86 (–CH₂–CH₃), 10.69 (–CH₂–CH₃).

N-(p-fluoro) benzyl-2-hydroxyisobutylamide (1g). Yield 28% (mp: 73–74.5, hexane). ¹H NMR (500 MHz, CDCl₃) δ 7.27–6.97 (m, 5H, Ar + NH), 4.41 (d, J = 6.0 Hz, 2H, –NH–CH₂–Ar), 2.22 (s, 1H, –OH), 1.48 (s, 6H, (–CH₃)₂). ¹³C NMR (126 MHz, CDCl₃) δ 176.02 (CO), 163.16, 161.20 (C–F), 134.07 – 115.48 (Ar), 73.78 (–C–OH), 42.57(–NH–CH₂–), 28.04 ((–CH₃)₂).

Synthesis of N-derivative-1,2,3-oxathiazolidine-4-one-2,2-dioxides 3(a, c–e, g). First, we synthesized the monoxides as previously described for cyclic sulfamates⁵. To a mixture of N-substituted amide-2-hydroxyisobutylamide (3 mmol) and triethylamine (13 mmol) in CH₂Cl₂ anhydrous (8 mL) at 0 °C, thionyl chloride (4 mmol) in CH₂Cl₂ anhydrous (4 mL) was added dropwise. The mixture was stirred under N₂ overnight and concentrated to dryness under reduced pressure to give N-derivative-1,2,3 oxathiazolidine-4-one-2-oxides as yellow oils. Then, the dioxides were obtained after oxidation with NaIO₄ and RuCl₃·6H₂O:^{18–20} An aqueous solution of NaIO₄ (7 mmol) and ruthenium chloride was added dropwise to a solution of N-derivative-1,2,3-oxathiazolidine-4-one-2-oxides (4.5 mmol) in acetonitrile (6 mL) and dichloromethane (6 mL) at 0 °C. The mixture was warmed to room temperature and an hour later extracted twice with CH₂Cl₂. The organic phases were combined, washed with water and brine, dried (Na₂SO₄) and concentrated to dryness. The residue obtained was flash chromatography on silica-gel 60 (70–230 mesh, Merck) and mixtures of CH₂Cl₂/hexane to give a white solid for all the compounds excluding **3a**.



Scheme 1. Synthetic route used in this investigation: (I) Ammonolysis reaction: MW radiation or catalyst, N₂ atmosphere, (II) Cyclization reaction: SOCl₂, triethylamine, (III) Oxidation reaction: NaIO₄, RuCl₃·6H₂O. Code for compounds: (1) α -hydroxyamide, (2) N-derivative-1,2,3-oxathiazolidine-4-one-2-oxide, (3) N-derivative-1,2,3-oxathiazolidine-4-one-2,2-dioxide. And a = hexyl, b = isopropyl, c = isobutyl, d = cyclohexyl, e = 1-methylbenzyl, f = 1-ethylbenzyl, g = p-fluorbenzyl.

3-hexyl-5,5-dimethyl-1,2,3-oxathiazolidine-4-one-2,2-dioxide (3a). Yield 25% (oil). ¹H NMR (500 MHz, CDCl₃) δ 3.67 (*m*, 2H, -CH₂-N), 1.79 (*m*, 2H, -CH₂), 1.76 (*s*, 6H, (-CH₃)₂), 1.34–1.29 (*m*, 6H, -CH₂), 0.91 (*t*, *J* = 6.8 Hz, 3H, -CH₃). ¹³C NMR (126 MHz, CDCl₃) δ 168.38 (CO), 93.26 ((CH₃)₂-C-O-), 42.03 (-N-CH-), 30.98 (-CH₂-CH₂-N-), 27.46 (-CH₂-(CH₂)₃-N-), 26.09 (-CH₂-(CH₂)₂-N-), 24.35 (-CH₂-(CH₂)₄-N-), 22.49 ((-CH₃)₂), 13.85 (-CH₃).

3-(1-isobutyl) 5,5-dimethyl-1,2,3-oxathiazolidine-4-one-2,2-dioxide (3c). Yield 55% (mp: 40–41, hexane). ¹H NMR (500 MHz, CDCl₃) δ 3.49 (*d*, *J* = 7.7 Hz, 2H, -N-CH₂-), 2.30 – 2.19 (*m*, 1H, -CH-CH₃), 1.77 (*s*, 6H, (-CH₃)₂), 1.00 (*d*, *J* = 6.7 Hz, 6H, -CH-CH₃). ¹³C NMR (126 MHz, CDCl₃) δ 168.90 (CO), 93.21 ((CH₃)₂-C-O-), 48.99 (-N-CH₂-), 27.13 (-N-CH₂-CH-), 24.44 ((-CH₃)₂), 19.72 (-N-CH₂-CH-CH₃).

3-cyclohexyl-5,5-dimethyl-1,2,3-oxathiazolidine-4-one-2,2-dioxide (3d). Yield 71% (mp: 59–60, hexane). ¹H NMR (500 MHz, CDCl₃) δ 4.00–3.92 (*m*, 1H, -CH-), 2.06 – 1.17 (*m*, 10H, cyclohexyl), 1.73 (*s*, 6H, (-CH₃)₂) ¹³C NMR (126 MHz, CDCl₃) δ 168.46 (CO), 91.81 ((CH₃)₂-C-O-), 56.05 (-N-CH-), 29.77, 25.71, 24.82 (cyclohexyl), 24.28 ((-CH₃)₂).

3-(1-methyl) benzyl-5,5-dimethyl-1,2,3-oxathiazolidine-4-one-2,2-dioxide (3e). Yield 58% (mp: 66–67, hexane). ¹H NMR (500 MHz, CDCl₃) δ 7.53 – 7.27 (*m*, 5H, Ar), 5.32 (*q*, 1H, -CH), 1.94 (*d*, *J* = 7.3 Hz, 3H, CH-CH₃), 1.81 (*s*, 3H, -CH₃), 1.51 (*s*, 3H, -CH₃) ¹³C NMR (126 MHz, CDCl₃) δ 163.06 (CO), 133.81–115.44 (Ar), 73.24 ((CH₃)₂-C-O-), 41.68 (-N-CH-), 27.55 ((-CH₃)₂), 27.20 (-CH-CH₃).

3-p-fluorbenzyl-5,5-dimethyl-1,2,3-oxathiazolidine-4-one-2,2-dioxide (3g). Yield 52% (mp: 86–87, dichloromethane/hexane). ¹H NMR (500 MHz, CDCl₃) δ 7.47 – 7.39 (*m*, 2H, Ar), 7.08 (*m*, 2H, Ar), 4.77 (*s*, 2H, -CH₂-Ar), 1.76 (*s*, 6H, (-CH₃)₂). ¹³C NMR (126 MHz, CDCl₃) δ 168.44 (CO), 163.89, 161.92 (C-F), 130.87 – 115.82 (Ar), 93.56 ((CH₃)₂-C-O-), 44.72 (-N-CH₂-), 24.30 ((-CH₃)₂).

Biological assays

In vivo test. We used male albino mice (18–23 g) provided by the Faculty of Veterinary, of the National University of La Plata. They were maintained under a regime of 12-h light/dark cycle and allowed free access to food and water. The animal care for the experimental protocols was conducted in accordance with the National Institutes of Health (NIH) guidelines for the Care and Use of Laboratory Animals and it was approved by the Ethical Committee of Exact Sciences Faculty of University of La Plata. Mice were randomized to different treatments. Candidate's solutions were performed in polyethyleneglycol 400 (PEG 400) at a rate of 3 mL/kg body weight and physiological solution was added up to a maximum volume of 7 mL/kg. Mice were *i. p.* administered with the synthesized compounds at doses of 30 or 100 mg/kg and they were evaluated at 0.5 or 4 h.

Maximal electroshock seizures were provoked in mice by delivering a 60 Hz/50 mA electrical stimulus for 0.2 s via ear clip

electrodes by means of a UGO Basile equipment. In these conditions, normal mice experience maximal seizures, characterized by a short period of tonic flexion followed by a longer period of tonic extension of the hind limbs and a final clonic episode⁹. Three minutes before induction of convulsion, all animals were evaluated in the Rotorod test. Rotorod equipment consists of a fluted roll divided by opaque discs rotating at a speed of 6 rpm. Animals were arranged on the cylinder and the ability to maintain balance on the rotarod for 1 min, in three consecutive tests, was evaluated. The inability of animals to maintain balance during the three tests, showing ataxia and sedation, was considered a sign of neurotoxicity²¹. Quantitative studies in MES test were conducted for **1g** at the previously determined time of peak effect (TPE). The ED⁵⁰ was determined by treating groups of six albino mice. Different doses were used for each drug at TPE. The method of Litchfield and Wilcoxon was used to compute the ED50 value²².

Electrophysiology. The electrophysiological recordings were performed using the patch-clamp technique in HEK293 cell line stably expressing the hNav1.2 channel isoform (a kind gift from GlaxoSmithKline, Stevenage, UK). The standard tight-seal whole-cell configurations of the patch-clamp technique was used to record macroscopic currents²³. Whole-cell currents were filtered with a 4-pole lowpass Bessel filter (Axopatch 200A amplifier) at 2 kHz and digitized (Digidata 1440, Molecular devices) at a sample frequency of 200 kHz (5 μ s). Once the whole-cell configuration was obtained, current stability was evaluated with a 15 ms-voltage-clamp step from a holding potential of -80 mV to a test potential of -20 mV repeated each 10 s. The time needed for the stabilization was variable (approximately 10 min). The same voltage-clamp step protocol was applied in the control (vehicle) or in the presence of compounds **1e**, **1g**, **3e** and **3g**, dissolved in 0.1% dimethylsulphoxide. After current stabilization on each condition, the voltage dependence of the steady-state inactivation of sodium channels was evaluated using a double voltage step protocol, where the same depolarization to -10 mV followed different pre-conditioning 2.5 s steps (from -130 to -40 mV). The available fraction of sodium channels at each membrane potential (IVc/I_{max}) was calculated as the ratio of peak sodium current measured at -10 mV, at each pre-conditioning voltage test pulse (IVc) and the maximum peak current observed (I_{max}). The relationship between the available fraction of sodium channels and the pre-conditioning (named h curve) was plotted and fitted with a Boltzmann equation (Equation (1)):

$$IVc/I_{max} = 1/(1 + \exp((V_h - V)/k)) \quad (1)$$

where the available fraction is given as IVc/I_{max}, V_h is the potential of half-maximal inactivation and k is the slope parameter. Statistical significance of the changes in the V_h parameter induced by the compounds was tested with F method (GraphPad Prism). More details of the experiment are given in [Supporting online material](#).

Docking simulations. The molecules were docked into the model of the 3D structure of the α -subunit of the human Nav1.2

(open-pore conformation) previously constructed by us²⁴. The “docking active site” was defined based on the experimental data, and includes residues numbered from Phe1764 to Tyr1771 as important for the interactions of the channel with known ACDs²⁵. Previous analyses of the performance of different docking protocols allowed us to select Autodock Vina²⁶ as the best method to discriminate known binders from non-binders of Nav1.2 through the docking score, so the conditions of the docking are already reported. We set the cut-off value as -8.1 Kcal/mol to differentiate active from inactive compounds, which has associated specificity and sensibility rates of 80% and 88%, respectively, in the receiver operating characteristic (ROC) curve of the set of compounds used for the validation of the protocol²⁴.

Results and discussion

Chemistry

The synthetic route followed in this investigation is shown in Scheme 1.

Synthesis of *N*-substituted 2-hydroxyisobutyl methyl amides. The α -hydroxyamides 1(a–g) were synthesized by ammonolysis of 2-hydroxyisobutyl methyl ester (Scheme 1). Compounds **1a**, **1c**, **1e** and **1g** were achieved under a solvent-free environment and microwave (MW)-assisted heating⁵. In these conditions, compounds **1b**, **1d** and **1f** were obtained with low yields. To improve the synthetic method for these amides, we conducted the reactions with a conventional heating system, and we used TBD as catalyst. The selection of this compound was supported by previous studies about the synthesis of other secondary and tertiary amides under solvent-free conditions²⁷.

Synthesis of *N*-derivatives-5,5-dimethyl oxathiazolidine-4-one-2,2-dioxides. The cyclization reaction of the resulting α -hydroxyamides to get the corresponding sulphamates was carried out following the conditions previously described for cyclic sulphamates (Scheme 1)^{5,18–20}. Initially we obtained the cyclic monoxides through the reaction of amides with thionyl chloride and triethylamine. Then, the compounds were oxidized with NaIO₄ and RuCl₃ to yield the final dioxide derivatives. *N*-isopropyl (**2b** and **3b**) and (1-ethyl) benzyl (**2f** and **3f**) derivatives were not obtained in these conditions, so they were not evaluated. The yields of the reactions are in the range between 25% and 71% for pure compounds.

In vivo tests. We followed the standard procedures proposed by the Epilepsy Therapy Screening Program (ETSP) of the NIH⁹, which is described in the Materials and Methods section. In Table 1, we report the results of MES test after the administration of the compounds in terms of the fraction of animals that did not show hind limbs tonic extension for each dose/time group. The primary toxicity of the drugs (signs of sedation and/or ataxia) was measured by the standardized Rotorod test, also included in the primary phase of the ETSP⁹.

The compounds were administered to mice intraperitoneally at the lower doses of the program (30, 100 mg/kg), and all the assays were performed at 0.5 and 4 h. Table 1 includes the classification of the structures according to the following criteria²⁸. Class (1): compound with anticonvulsant activity at 100 mg/kg or less, Class (2): compound with anticonvulsant activity at doses higher than 100 mg/kg, Class (3): inactive compound at any doses up to 300 mg/kg, and Class (4): inactive compound at 300 mg/kg and toxic at 30 mg/kg or less. The results achieved from the assays showed that all the structures were active against MES test, which allowed us to classify them as class 1. In fact, most of the structures exhibited protection against the induced seizure at the

Table 1. Pharmacological profile (phase I) of the synthesized compounds.

Compound	Dose (mg/Kg)	MES ^a		Rotorod ^b		Class
1a	30	1/2	2/3	0/2	0/3	1
	100	2/2	2/2	0/2	0/2	
1b	30	0/2	3/4	0/2	0/4	1
	100	1/2	2/4	0/2	0/4	
1c	30	1/3	1/3	0/3	0/3	1
	100	1/3	2/3	0/3	0/3	
1d ⁽⁸⁾	30	1/3	3/3	0/3	0/3	1
	100	3/3	2/3	0/3	0/3	
1e	30	0/3	1/3	0/3	0/3	1
	100	3/3	1/3	0/3	0/3	
1f	30	2/5	0/2	0/5	0/2	1
	100	3/5	0/2	0/5	0/2	
1g	30	3/4	0/2	0/4	0/2	1
	100	4/4	0/2	0/4	0/2	
3a	30	0/2	0/2	0/2	0/2	1
	100	2/4	2/4	0/4	0/4	
3c	30	0/2	0/2	0/2	0/2	1
	100	1/2	0/2	0/2	0/2	
3d	30	4/4	1/4	0/4	0/4	1
	100	(–)	(–)	(–)	(–)	
3e	30	1/2	1/2	0/2	0/2	1
	100	0/2	1/2	0/2	0/2	
3g	30	1/5	1/4	0/3	0/2	1
	100	0/2	0/2	0/2	0/2	

^aNumber of protected animals relative to the total number of mice tested in MES at each time and concentration.

^bNumber of animals with sedative effects relative to the total number of mice tested at each time and concentration. Compound **3d** was not tested at dose of 100 mg/kg due to solubility problems, referenced as (–). (8) See reference in Bibliographic section.

lower doses tested (30 mg/kg). These results are encouraging since class 1 includes the most promising candidates for the next step of the biological testing²⁸. In addition to the anticonvulsant activity found for the compounds, no signs of sedation and/or ataxia were detected in the Rotorod test, which is important in terms of the safety profile of the active structures. Compound **3d** had solubility problems, so it was not possible to evaluate them at the highest dose with the recommended vehicles of the ETSP Program⁶.

ED⁵⁰ value was calculated for compound **1g**, since it showed strong anticonvulsant action at both doses evaluated in MES test. Again, we followed the standard procedures for the calculation, described in the Materials and Methods section. Essentially, ED⁵⁰ measures the dose of drug that is effective in 50% of the tested animals⁹. This value is calculated at the time of peak effect (TPE), which has to be previously identified⁹. The final ED⁵⁰ value of **1g** was 29 mg/kg, which is equivalent to 0,106 mmol/kg (TPE = 0.5 h). This result is interesting in terms of potency, since it is in the range of ED⁵⁰ values measured for classical ACDs in the same test. For example, phenytoin showed ED⁵⁰ values of 0.0218 mmol/kg; whereas valproic acid, a representative ACD of broad spectrum, showed an ED⁵⁰ value of 1.962 mmol/kg. Also important is the fact that all the structures passed the Rotorod test, which detects neurotoxicity in terms of sedation or ataxia; and none of the mice treated with the compounds died during the assays.

In silico studies

To explore one of the possible mechanisms of action of the synthesized compounds we analyse them as sodium channel blockers. The blockage of VGSC is a validated mechanism of action of many ACD with probed clinical efficacy^{7,11,12}. Among the four different VGSCs isoforms recognized in CNS (Nav1.1, Nav1.2, Nav1.3

and Nav1.6), Nav1.2 is the molecular target with confirmed interaction with many ACDs^{11,12}.

Initially, the molecules were docked into the Nav1.2 channel with Autodock Vina software²⁶. As the 3D structure of human Nav1.2 is not available, we employed a 3D model of this macromolecule previously constructed in our laboratory²⁴. It includes the 3D architecture of the α -subunit of the Nav1.2 channel, which is functional on its own and comprises the region of interactions

with ACD. A docking score of -8.1 kcal/mol was defined as the threshold value to differentiate active from inactive compounds. This cut-off value was previously selected for the screening of a virtual database, since it shows a good balance between specificity and sensibility for the test set that validated the docking model (80% and 88%, respectively)²⁴. Table 2 shows the docking scores of the synthesized compounds.

Our docking results suggest that the amides are poorer candidates to block the Nav1.2 channel since none of them were able to pass the threshold value defined for active compounds according to the docking classificatory model (-8.1 Kcal/mol). Among cyclic structures, compounds **3e** and **3g** were predicted as active. It is worth mentioning that the docking protocol has been already validated and used to identify new Nav1.2 blockers in a previous investigation²⁴. Figure 2(A) shows the binding geometries of structures **3e** and **3g** into the docking active site, which includes residues of the ion conducting pore of the channel that interact with

Table 2. Docking scores of the synthesized compounds.

Compound	Score	Compound	Score
1a	-6.4	1g	-7.5
1b	-5.5	3a	-6.7
1c	-6.3	3c	-6.5
1d	-6.9	3d	-7.2
1e	-7.7	3e	-8.2
1f	-7.8	3g	-8.3




Figure 2. (A): Binding geometry of compounds **3e** and **3g** into the Nav1.2 active site predicted by the Autodock Vina docking algorithms. (B) binding geometry predicted for phenytoin. Carbon atoms are highlighted in pink, yellow and green for compounds **3e**, **3g** and phenytoin, respectively. Nitrogen, oxygen and fluorine atoms of the compounds are highlighted in blue, red and light blue, respectively. Residues that surround the ligand within 5 angstroms of distance are highlighted as sticks. Important aromatic residues are numbered in the figure. Hydrogen atoms are omitted for simplicity except for the non-aromatic hydrogen atoms of phenytoin.




Figure 3. Whole cell configuration with a voltage-clamp step protocol from -80 to -20 mV. (A) Typical traces of Na^+ currents in Nav 1.2 isoform, control and compound **1e** or **1g**, $100 \mu\text{M}$. (B) $p > 0.05$. No statistical differences were found for both compounds ($n = 4$).

known ACDs²⁵. The simulations suggest that the compounds direct their aromatic ring towards the region delimited by aromatic side chains of Phe1462 and Phe1754. In the docking conditions, the ACD phenytoin orientates its heterocycle and one of its aromatic rings to the same regions occupied by **3e** and **3g**, with a docking score of -9.9 kcal/mmol (Figure 2(B))²⁶. The overall orientation of **3e**, **3g** and phenytoin into the Nav1.2 channel is given as Supplemental online material (Figure S1).

Electrophysiology

The virtual strategy proposed only two compounds, **3e** and **3g**, as Nav1.2 blockers. Both structures showed anticonvulsant action in mice at the lower dose tested. On the other hand, the rest of compounds (which were predicted as inactive in the Nav1.2 model) showed protection against MES test.

To analyse if the contrast between the *in silico* predictions and the *in vivo* assays can be explained as a fail in the sensibility of the docking protocol, we selected two pairs of compounds (**1e-3e** and **1g-3g**) to test their effect in Nav1.2 currents using the patch-clamp technique. The rationale for compounds selection was to test the two heterocycles predicted as active, and their corresponding α -hydroxyamides, which were classified as not active in the docking simulations (Table 2).

The *in vitro* activity of compounds **1e**, **1g**, **3e** and **3g** was evaluated in the Na⁺ currents carried through the Nav1.2 channel isoform stably expressed in HEK 293 cells by using the whole-cell configuration. The current stability, before and after perfusion of the tested compounds, was monitored every 10 s by a 10 ms voltage step to -20 mV from a holding potential of -80 mV. The inhibitory activity was observed as decay in the peak amplitude of the Na⁺ currents. After current stabilization, and with the aim to evaluate the state-dependent inhibition, we tested the ability of these compounds to modify the steady-state inactivation curves (h curves) of the Nav1.2 channels. The h curve shows the available fraction of Na⁺ channels in condition to be activated (in resting state) as a function of the resting membrane potential (see Material and Methods section). The state-dependent inhibition, due to the stabilization of the inactivated state, is observed as a left-shift in the h curves, which means a reduction of available Na⁺ channel which is higher at more depolarized potential.

Amides **1e** and **1g** were not able to block Na⁺ current (Figure 3(A,B)) and did not change the steady state inactivation curves (Figure 4(A,B,C)), while the corresponding cyclic compounds **3e** and **3g** inhibited Na⁺ current (Figure 5(A,B)) and shifted the h curve to more hyperpolarized potentials, (Figure 6 (A,B,C)). These results are consistent with the docking model predictions.




Figure 4. Compounds **1e** and **1g** did not affect the Nav1.2 channel steady state inactivation curves. (A) Typical traces of the steady-state inactivation protocol, where Nav1.2 currents were activated by a depolarizing voltage step to -10 mV for 15 ms following 2500 ms hyperpolarizing pre-pulses ranging from -130 to -40 mV in the absence and in the presence of $100 \mu\text{M}$ of **1e** and **1g**. (B) Mean available fraction (I/I_{max}) values for compound **1e** or **1g** and their respect control plotted as function of membrane voltage (mV) and fitted to the Boltzmann function. (C) Mean V_h values obtained from plots showed in (B). No statically difference was observed ($p > 0.05$, $n = 4$ for each group). $V_{h\text{control}}(\mathbf{1e}) = -62.77 \pm 2.5$, $V_h(\mathbf{1e}) = -60.63 \pm 1.40$, $n = 4$. $V_{h\text{control}}(\mathbf{1g}) = -58.09 \pm 0.43$, $V_h(\mathbf{1g}) = -59.96 \pm 1.19$, $n = 4$.




Figure 5. Compounds **3e** and **3g** inhibited the Nav1.2 current. (A) Typical traces of Nav1.2 currents recorded in HEK 293 cells in the whole cell configuration with a voltage-clamp step protocol from -80 to -20 mV before and after $100 \mu\text{M}$ **3e** (up) and **3g** (down) extracellular perfusion. (B) Mean Nav1.2 currents values obtained from current showed in (A). $*p < 0.05$ indicates significant difference between control and compound **3e** (%Current Inhibition = 29.6%); $##p < 0.005$ indicates significant differences between control and compound **3g** group. (%Current Inhibition = 33%). Paired t -test $n = 4$, for each group.




Figure 6. Compounds **3e** and **3g** produced a state-dependent inhibition in Nav1.2 channel. (A) Typical traces of the steady-state inactivation protocol where Nav1.2 currents were activated by a depolarizing voltage step to -10 mV for 15 ms following 2500 ms hyperpolarizing pre-pulses ranging from -130 to -40 mV in the absence and in the presence of $100 \mu\text{M}$ of **3e** and **3g**. (B) Mean available fraction (I/I_{max}) values for compound **3e** or **3g** and their respect control plotted as function of membrane voltage (mV) and fitted to the Boltzmann function (Equation (1)). (C) V_h values obtained from plots showed in (B). $p < 0.05$. **, ### Significant differences between **3e**, **3g** and their respective control groups, $V_{h\text{control}}(\text{3e}) = -60.18 \pm 1.68$, $V_h(\text{e}) = -68.19 \pm 2.19$, $n = 5$, $V_{h\text{control}}(\text{3g}) = -74.76 \pm 1.26$, $V_h \text{ 3g} = -80.14 \pm 3.08$, $n = 4$.

As mentioned before, the electrophysiological assays confirmed our docking predictions, showing that the oxathiazolidine-4-one-2,2-dioxide derivatives **3e** and **3g** inhibit Na⁺ currents by left-shifting the steady-state inactivation curve, suggesting the interaction of these compounds with Nav1.2 channel.

Conclusions

In this investigation, we synthesized and studied the anticonvulsant action of new α -hydroxyimides and N-derivatives-1,2,3-oxathiazolidine-4-one-2,2-dioxides, which scaffold is a bioisosteric partner of the known ACD phenytoin. The compounds were tested in mice and they evidenced a promising anticonvulsant activity as well as a good safety profile at this pre-clinical stage. Particularly, structure **1g** shows an ED⁵⁰ comparable with classical ACDs.

Docking simulations suggested the interaction of two compounds of the set with the Nav1.2 target and patch clamp experiments were performed to corroborate the *in silico* predictions. These two structures are N-aromatic derivatives of 1,2,3-oxathiazolidine-4-one-2,2-dioxides. Conversely, N-aliphatic-derivatives and all the α -hydroxyamides were classified as non-active. However, they showed anticonvulsant action in mice. The differences observed between *in vitro* (and *in silico*) assays and *in vivo* experiments can be generated by multiple factors. First, post-transcriptional modifications such as alternative splicing, channel protein phosphorylation and/or glycosylation are capable to modify the pharmacological sensitivity of ion channels. Moreover, the activity of the channel blockers can be modified by the expression of auxiliary beta subunits and co-localization with other membrane proteins in native cells²⁹. A second factor is related with the selectivity of the compounds, since most ACDs can elicit the antiepileptic effect by acting in multiple targets. They are nonselective among neuronal Nav channels isoforms, and they can modify other isoforms (such Nav 1.1 and 1.6), other ions channels (such as K⁺ and Ca²⁺ channels), ionotropic receptors (like GABA-A and NMDA) and enzymes (GABA transaminase and glutamic acid decarboxylase)^{7,30}. Finally, the drug metabolism can produce active metabolites which were not tested in the docking protocol and *in vitro* experiments³¹.

Our electrophysiological experiments allowed us to explore the inhibitory mechanism of action of **3e** and **3g**. Both compounds showed inhibitory activity on Nav 1.2 isoform in the two protocols tested. Interestingly, the left shift produced in the h curve indicates that these compounds can stabilize the steady-state inactivation of the channel. This state-dependent mechanism in Nav channels is shared with ACDs such as phenytoin, carbamazepine and lamotrigine, among others^{32,33}. Nav channels are voltage dependent and have at least three well recognized states^{34,35}. When the cell membrane potential is hyperpolarized, the channel is in the resting closed state, then when the membrane potential rise, the channel turns to an open state and subsequently fall into a not conducting inactive state. The Nav channels are not able to open from this inactivated state and hyperpolarization is needed to return the channels to the resting state. In this way, the membrane potential value determines the fraction of Nav channels that are able to open after a depolarizing stimulus and trigger an action potential. So, drugs that stabilize the inactivated state show a higher inhibitory effect in cells where the membrane is more depolarized (are voltage-dependent). This is particularly interesting since, in epilepsy, the neurons responsible for seizure are hyper-excitable and this is, in part, due to a more positive membrane potential. Thus, the Nav

channel blocking effect of these drugs is greater in neurons involved in the seizure, reducing the probability of side effect induced by the channel block in normal neurons³⁶. Regarding future investigations on VGSC blockers, more studies will be completed in the future for N-derivatives of 5,5-dimethyl-1,2,3-oxathiazolidine-4-one-2,2-dioxide and their synthetic precursors, to propose their possible mechanisms of action and to optimize their anticonvulsant action. Finally, the discovery of new VGSC blockers will allow us to evaluate them in other biological assays related with CNS pathologies where the VGSCs are also implicated. Good examples would be depression and anxiety, two pathologies well recognized as comorbid with epilepsy.

Acknowledgements

L. Gavernet, P. Martin and V. Pastore are members of Consejo Nacional de Investigaciones Científicas y Técnicas de la República Argentina (CONICET). P. Palestro, L. Sabatier, and A. Enrique are fellowship holders of CONICET.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This work was supported by the Agencia de Promoción Científica y Tecnológica under Grants [PICT 3175–2013] and [PICT 0165–2016], CONICET, and Universidad Nacional de La Plata, Argentina. We gratefully acknowledge the support of NVIDIA Corporation with the donation of the Quadro M5000 GPU used for this research.

References

1. Prasad LK, Smyth H. 3D Printing technologies for drug delivery: a review. *Drug Dev Ind Pharm* 2016;42:1019–31.
2. Sirven JI, Noe K, Hoerth M, Drazkowski J. Antiepileptic drugs 2012: recent advances and trends. *Mayo Clin Proc* 2012;87: 879–89.
3. Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Thirteenth Eilat Conference on new antiepileptic drugs and devices (EILAT XIII). *Epilepsia* 2017;58:181–221.
4. W.H.O. Epilepsy. Fact sheet. No. 999; 2015.
5. Pastore V, Sabatier L, Enrique AV, et al. Synthesis and anticonvulsant activity of bioisosteres of trimethadione, N-derivative-1,2,3-oxathiazolidine-4-one-2,2-dioxides from α -hydroxyamides. *Bioorg Med Chem* 2013;21:841–6.
6. Putnam TJ, Merritt HH. Experimental determination of the anticonvulsant properties of some phenyl derivatives. *Science* 1937;85:525–6.
7. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. *Neurotherapeutics* 2007;4:18–61.
8. Abou-Khalil BW. Update on antiepileptic drugs 2019. *Continuum (Minneapolis)* 2019;25:508–36.
9. Kehne JH, Klein BD, Raeissi S, Sharma S. The National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP). *Neurochem. Res* 2017;42:1894–903.

10. Pastore V, Wasowski C, Higgs J, et al. A synthetic bioisoster of trimethadione and phenytoin elicits anticonvulsant effect, protects the brain oxidative damage produced by seizures and exerts antidepressant action in mice. *Eur Neuropsychopharmacol* 2014;24:1405–14.
11. Vohora D, Saraogi P, Yazdani M, et al. Recent advances in adjunctive therapy for epilepsy: focus on sodium channel blockers as third-generation antiepileptic drugs. *Drugs Today* 2010;46:265–77.
12. Brodie MJ. Antiepileptic drug therapy the story so far. *Seizure* 2010;19:650–5.
13. Banfi L, Riva R. The passerini reaction. *Org React* 2005;65: 1–140.
14. Saegusa T, Taka-ishi N, Ito Y. The thermal rearrangement and degradation of 2,3-Bis(alkylimino)oxetane. *Bull Chem Soc Japan* 1971;44:1121–5.
15. Hagedorn I, Eholzer U. Single-step synthesis of α -hydroxy acid amides by a modification of the Passerini reaction. *Chemische Berichte* 1965;98:936–40.
16. Hagedorn I, Eholze U. N-Monosubstituted α -hydroxycarboxamides. *DE* 1964;1173082:19640702.
17. Shapiro L, Rose IM, Testa FC, et al. N-Substituted oxazolidinediones. *J Am Chem Soc* 1959;81:6498–504.
18. Meléndez RE, Lubell WD. Synthesis and reactivity of cyclic sulfamidites and sulfamidates. *Tetrahedron* 2003;59:2581–616.
19. Posakony JJ, Grierson JR, Tewson TJ. New routes to N-alkylated cyclic sulfamidates. *J Org Chem* 2002;67:5164–9.
20. White GJ, Garst ME. Cyclic sulfamate from N-substituted 2-amino-3-phenyl-1-propanol and its nucleophilic reactions. *J Org Chem* 1991;56:3177–8.
21. Jones BJ, Roberts DJ. The quantitative measurement of motor incoordination in naive mice using an accelerating rotarod. *J Pharm Pharmacol* 1968;20:302–4.
22. Litchfield JT, Wilcoxon F. A simplified method of evaluating dose-effect experiments. *J Pharmacol Exp Ther* 1949;96: 99–113.
23. Hamill O, Marty A, Neher E, et al. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. *Pflugers Arch* 1981;391: 85–100.
24. Palestro P, Enrique AV, Goicoechea S, et al. Searching for new leads to treat epilepsy: target-based virtual screening for the discovery of anticonvulsant agents. *J Chem Inf Model* 2018;58:1331–42.
25. Boiteux C, Vorobyov I, French RJ, et al. Local anesthetic and antiepileptic drug access and binding to a bacterial voltage-gated sodium channel. *Proc Natl Acad Sci USA* 2014;111: 13057–62.
26. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J Comp Chem* 2010;31: 455–61.
27. Sabot KC, Kumar A, Meunier S, Mioskowski C. A convenient aminolysis of esters catalyzed by 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD) under solvent-free conditions. *Tetrahedron Lett* 2007;48:3863–6.
28. Malawska B, Kulig K, Śpiewak A, Stables JP. Investigation into new anticonvulsant derivatives of alpha-substituted N-benzylamides of gamma-hydroxy- and gamma-acetoxybutyric acid. Part 5: search for new anticonvulsant compounds. *Bioorg Med Chem* 2004;12:625–32.
29. Uebachs M, Albus C, Opitz T, et al. Loss of β 1 accessory Na⁺ channel subunits cause failure of carbamazepine, but not of lacosamide, in blocking high-frequency firing via differential effects on persistent Na⁺ currents. *Epilepsia* 2012; 53:1959–67.
30. Younus I, Reddy DS. A resurging boom in new drugs for epilepsy and brain disorders. *Expert Rev Clin Pharmacol* 2018; 11:27–45.
31. LaPenna P, Tormoehlen LM. The pharmacology and toxicology of third-generation anticonvulsant drugs. *J Med Toxicol* 2017;13:329–42.
32. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. *Nat Rev Neurosci* 2004;5:553–64.
33. Nardi A, Damann N, Hertrampf T, Kless A. Advances in targeting voltage-gated sodium channels with small molecules. *ChemMedChem* 2012;7:1712–40.
34. Denac H, Mevissen M, Scholtysik G. Structure, function and pharmacology of voltage-gated sodium channels. *Naunyn-Schmiedeberg's Arch Pharmacol* 2000;362:453–79.
35. Bertrand D, Biton B, Licher T, et al. Functional studies of sodium channels: from target to compound identification. *Curr Protoc Pharmacol* 2016;7:9.21.1–.21.35.
36. Goldin AL. Mechanisms of sodium channel inactivation. *Curr Opin Neurobiol* 2003;13:284–90.